{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:18:20Z","timestamp":1788265100303,"version":"build-2803163510"},"reference-count":34,"publisher":"Becaris Publishing Limited","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Indirect treatment comparisons (ITCs), as outlined in NICE and ISPOR guidance, require careful evaluation of cross-trial heterogeneity to ensure valid comparisons, particularly in rare diseases with limited evidence. C3 glomerulopathy (C3G) is an ultra-rare, complement-mediated kidney disease with high unmet need, making appropriate application of ITC frameworks especially critical. This appraisal evaluates the feasibility of applying ITC principles to compare Phase III trials of iptacopan (APPEAR-C3G) and pegcetacoplan (VALIANT) in the absence of head-to-head evidence.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    Feasibility of an ITC in C3G was assessed through critical appraisal of APPEAR-C3G and VALIANT randomized controlled trials, focusing on alignment of eligibility criteria, baseline characteristics and outcome definitions, in line with NICE DSU TSD-18, CHTE2020 and ISPOR guidance. A systematic literature review (SLR) was then conducted to identify published ITCs comparing iptacopan and pegcetacoplan in C3G, which were evaluated for methodological rigor, transparency and credibility according to NICE and ISPOR recommendations.\n                    <jats:bold>Results:<\/jats:bold>\n                    Substantial heterogeneity was observed between APPEAR-C3G and VALIANT. Overlap was limited to small subpopulations, with imbalances in baseline characteristics, differences in end point reporting, and noncomparable placebo responses. These issues indicate that anchored ITCs are not feasible using currently available data without extensive adjustments that conflict with NICE and ISPOR guidance. The SLR identified one ITC poster with limited methodology comparing these trials. However, when the results were subsequently published in a manuscript, crucial methodological details including justification of effect modifiers, modeling diagnostics, analytic procedures, were still unavailable. Other concerns, such as using standard matching-adjusted indirect comparison methodology in the presence of substantial cross-trial heterogeneity, and the resulting limited ESS observed frequently in rare diseases, were confirmed, thus undermining credibility of conclusions.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    ITCs in C3G face significant methodological challenges due to pronounced trial heterogeneity and small sample sizes inherent to this ultra-rare disease. These limitations complicate the conduct and interpretation of arising ITCs, highlighting the need for transparent and methodologically robust approaches. Consequently, payers, decision makers, and HTA bodies should interpret existing C3G ITCs with caution. These findings inform broader application of ITC methods in rare diseases, identifying areas for future evidence generation and analytical innovation.\n                  <\/jats:p>","DOI":"10.57264\/cer-2026-0054","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:11:51Z","timestamp":1786043511000},"source":"Crossref","is-referenced-by-count":0,"title":["Methodological pitfalls in indirect treatment comparisons: insights from a recent systematic review and analysis for C3 glomerulopathy"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5662-8647","authenticated-orcid":false,"given":"Brian","family":"Hutton","sequence":"first","affiliation":[{"name":"Ottawa Hospital Research Institute, Methods &amp; Implementation Research Program, Ottawa, Ontario K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8980-2223","authenticated-orcid":false,"given":"James","family":"Fotheringham","sequence":"additional","affiliation":[{"name":"Faculty of Population Health, School of Medicine &amp; Population Health, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0809-7035","authenticated-orcid":false,"given":"Andrew","family":"Ervin","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals UK Limited, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0993-9681","authenticated-orcid":false,"given":"Raisa","family":"Sidhu","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9075-7661","authenticated-orcid":false,"given":"Corey","family":"Lourenco","sequence":"additional","affiliation":[{"name":"CRG-EVERSANA Canada Inc., Burlington, Ontario L7N 3H8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1415-8055","authenticated-orcid":false,"given":"Imtiaz A","family":"Samjoo","sequence":"additional","affiliation":[{"name":"CRG-EVERSANA Canada Inc., Burlington, Ontario L7N 3H8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3613-760X","authenticated-orcid":false,"given":"Chris","family":"Cameron","sequence":"additional","affiliation":[{"name":"CRG-EVERSANA Canada Inc., Burlington, Ontario L7N 3H8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6817-3745","authenticated-orcid":false,"given":"Bridget","family":"Dunne","sequence":"additional","affiliation":[{"name":"Novartis Ireland Ltd., Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"key":"e_1_3_9_3_2","unstructured":"Welton NJ Phillippo D Owen R CHTE2020 sources and synthesis of evidence: update to evidence synthesis methods (2020). https:\/\/sheffield.ac.uk\/nice-dsu\/methods-development\/chte2020-sources-and-synthesis-evidence"},{"issue":"2","key":"e_1_3_9_4_2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0272989X17725740","article-title":"Methods for population-adjusted indirect comparisons in health technology appraisal","volume":"38","author":"Phillippo DM","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S Methods for population-adjusted indirect comparisons in health technology appraisal. Med. Decis. Making 38(2), 200\u2013211 (2018).","journal-title":"Med. Decis. Making"},{"issue":"4","key":"e_1_3_9_5_2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1","volume":"14","author":"Jansen JP","year":"2011","unstructured":"Jansen JP, Fleurence R, Devine B Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 14(4), 417\u2013428 (2011).","journal-title":"Value Health"},{"issue":"2","key":"e_1_3_9_6_2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jval.2014.01.004","article-title":"Indirect treatment comparison\/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report","volume":"17","author":"Jansen JP","year":"2014","unstructured":"Jansen JP, Trikalinos T, Cappelleri JC Indirect treatment comparison\/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health 17(2), 157\u2013173 (2014).","journal-title":"Value Health"},{"issue":"3","key":"e_1_3_9_7_2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41581-018-0107-2","article-title":"C3 glomerulopathy\u2014understanding a rare complement-driven renal disease","volume":"15","author":"Smith RJ","year":"2019","unstructured":"Smith RJ, Appel GB, Blom AM C3 glomerulopathy\u2014understanding a rare complement-driven renal disease. Nat. Rev. Nephrol. 15(3), 129\u2013143 (2019).","journal-title":"Nat. Rev. Nephrol."},{"issue":"6","key":"e_1_3_9_8_2","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000507254","article-title":"Update on C3 glomerulopathy: a complement-mediated disease","volume":"144","author":"Caravaca-Font\u00e1n F","year":"2020","unstructured":"Caravaca-Font\u00e1n F, Lucientes L, Cavero T, Praga M. Update on C3 glomerulopathy: a complement-mediated disease. Nephron 144(6), 272\u2013280 (2020).","journal-title":"Nephron"},{"issue":"4","key":"e_1_3_9_9_2","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies","volume":"82","author":"Servais A","year":"2012","unstructured":"Servais A, No\u00ebl L-H, Roumenina LT Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 82(4), 454\u2013464 (2012).","journal-title":"Kidney Int."},{"issue":"1","key":"e_1_3_9_10_2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2215\/CJN.04700513","article-title":"C3 glomerulopathy: clinicopathologic features and predictors of outcome","volume":"9","author":"Medjeral-Thomas NR","year":"2014","unstructured":"Medjeral-Thomas NR, O'Shaughnessy MM, O'Regan JA C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin. J. Am. Soc. Nephrol. 9(1), 46\u201353 (2014).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"e_1_3_9_11_2","first-page":"1993","volume-title":"GeneReviews\u00ae [Internet]","author":"Mart\u00edn B","year":"2018","unstructured":"Mart\u00edn B, Smith RJ. C3 Glomerulopathy. In: GeneReviews\u00ae [Internet]. Adam MP, Feldman J, Mirzaa GM (Eds). University of Washington, WA, USA, 1993\u20132024 (2018). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1425\/"},{"issue":"1","key":"e_1_3_9_12_2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1053\/j.akdh.2025.12.001","article-title":"Complement 3 glomerulopathy revisited: bridging pathogenesis and therapy in the new era","volume":"33","author":"Yandian F","year":"2026","unstructured":"Yandian F, Fervenza FC, Caravaca-Font\u00e1n F. Complement 3 glomerulopathy revisited: bridging pathogenesis and therapy in the new era. Adv. Kidney Dis. Health 33(1), 78\u201391 (2026).","journal-title":"Adv. Kidney Dis. Health"},{"issue":"2","key":"e_1_3_9_13_2","doi-asserted-by":"crossref","first-page":"103705","DOI":"10.1016\/j.ekir.2025.11.029","article-title":"Complement-mediated kidney diseases: role of alternative pathway in glomerular inflammation","volume":"11","author":"Barratt J","year":"2025","unstructured":"Barratt J, Garred P, Lafayette RA, Zhang H, Floege J. Complement-mediated kidney diseases: role of alternative pathway in glomerular inflammation. Kidney Int. Rep. 11(2), 103705 (2025).","journal-title":"Kidney Int. Rep."},{"issue":"1","key":"e_1_3_9_14_2","first-page":"gfae069-0029","article-title":"# 1196 C3G and ic-MPGN across the life span: findings from the European Rare Kidney Disease Registry","volume":"39","author":"Schaefer F","year":"2024","unstructured":"Schaefer F, Hofstetter J, Ruiz EM # 1196 C3G and ic-MPGN across the life span: findings from the European Rare Kidney Disease Registry. Nephrol. Dial. Transplant. 39(Suppl. 1), gfae069-0029 (2024).","journal-title":"Nephrol. Dial. Transplant."},{"issue":"1","key":"e_1_3_9_15_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ekir.2024.09.017","article-title":"Challenges in the diagnosis and management of immune complex-mediated membranoproliferative glomerulonephritis and complement 3 glomerulopathy","volume":"10","author":"Bomback AS","year":"2025","unstructured":"Bomback AS, Charu V, Fakhouri F. Challenges in the diagnosis and management of immune complex-mediated membranoproliferative glomerulonephritis and complement 3 glomerulopathy. Kidney Int. Rep. 10(1), 17\u201328 (2025).","journal-title":"Kidney Int. Rep."},{"issue":"3","key":"e_1_3_9_16_2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.kint.2025.06.003","article-title":"Quantifying association of early proteinuria and estimated glomerular filtration rate changes with long-term kidney failure in C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis using the United Kingdom RaDaR Registry","volume":"108","author":"Masoud S","year":"2025","unstructured":"Masoud S, Wong K, Pitcher D Quantifying association of early proteinuria and estimated glomerular filtration rate changes with long-term kidney failure in C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis using the United Kingdom RaDaR Registry. Kidney Int. 108(3), 455\u2013469 (2025).","journal-title":"Kidney Int."},{"issue":"10","key":"e_1_3_9_17_2","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.ekir.2022.07.004","article-title":"Alternative complement pathway inhibition with iptacopan for the treatment of C3 glomerulopathy-study design of the APPEAR-C3G trial","volume":"7","author":"Bomback AS","year":"2022","unstructured":"Bomback AS, Kavanagh D, Vivarelli M Alternative complement pathway inhibition with iptacopan for the treatment of C3 glomerulopathy-study design of the APPEAR-C3G trial. Kidney Int. Rep. 7(10), 2150\u20132159 (2022).","journal-title":"Kidney Int. Rep."},{"key":"e_1_3_9_18_2","unstructured":"Novartis Pharmaceuticals. Study of efficacy and safety of iptacopan in patients with C3 glomerulopathy (APPEAR-C3G). ClinicalTrials.gov Identifier: NCT04817618. Last update posted 2025 Mar 4. (2025). Available at: https:\/\/clinicaltrials.gov\/study\/NCT04817618"},{"issue":"10512","key":"e_1_3_9_19_2","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(25)01148-1","article-title":"Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, Phase III study","volume":"406","author":"Kavanagh D","year":"2025","unstructured":"Kavanagh D, Bomback AS, Vivarelli M Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, Phase III study. Lancet 406(10512), 1587\u20131598 (2025).","journal-title":"Lancet"},{"issue":"22","key":"e_1_3_9_20_2","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1056\/NEJMoa2501510","article-title":"Trial of pegcetacoplan in C3 glomerulopathy and immune-complex MPGN","volume":"393","author":"Fakhouri F","year":"2025","unstructured":"Fakhouri F, Bomback AS, Ariceta G Trial of pegcetacoplan in C3 glomerulopathy and immune-complex MPGN. N. Engl. J. Med. 393(22), 2210\u20132220 (2025).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_9_21_2","unstructured":"Apellis Pharmaceuticals. Phase III study assessing the efficacy and safety of pegcetacoplan in patients with C3 glomerulopathy or immune-complex membranoproliferative glomerulonephritis (VALIANT). ClinicalTrials.gov Identifier: NCT05067127. Last update posted 2025 Aug 6. (2025). Available at: https:\/\/clinicaltrials.gov\/study\/NCT05067127"},{"issue":"10","key":"e_1_3_9_22_2","first-page":"10.1681","article-title":"VALIANT: a randomized, multicenter, double-blind, placebo (PBO)-controlled, Phase III trial of pegcetacoplan for patients with native or post-transplant recurrent glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN): SA-OR92","volume":"35","author":"Nester CM","year":"2024","unstructured":"Nester CM, Bomback AS, Iraola MGA VALIANT: a randomized, multicenter, double-blind, placebo (PBO)-controlled, Phase III trial of pegcetacoplan for patients with native or post-transplant recurrent glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN): SA-OR92. J. Am. Soc. Nephrol. 35(Suppl. 10), 10.1681 (2024).","journal-title":"J. Am. Soc. Nephrol."},{"key":"e_1_3_9_23_2","unstructured":"Gemeinsamer Bundesausschuss. Dossier zur Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V. Anhang 4-G. (2026). https:\/\/www.g-ba.de\/downloads\/92-975-9551\/2026_02_10_Modul4D_Pegcetacoplan_Anhang4_G.pdf"},{"issue":"5","key":"e_1_3_9_24_2","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1177\/0272989X13485157","article-title":"Evidence synthesis for decision making 3: heterogeneity\u2014subgroups, meta-regression, bias, and bias-adjustment","volume":"33","author":"Dias S","year":"2013","unstructured":"Dias S, Sutton AJ, Welton NJ, Ades A. Evidence synthesis for decision making 3: heterogeneity\u2014subgroups, meta-regression, bias, and bias-adjustment. Med. Decis. Making 33(5), 618\u2013640 (2013).","journal-title":"Med. Decis. Making"},{"key":"e_1_3_9_25_2","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021).","journal-title":"BMJ"},{"issue":"10","key":"e_1_3_9_26_2","first-page":"10.1681","article-title":"Clinical efficacy of pegcetacoplan vs. iptacopan in patients with C3 glomerulopathy: indirect treatment comparisons: SA-PO0826","volume":"36","author":"Dixon BP","year":"2025","unstructured":"Dixon BP, Bomback AS, Rich CS Clinical efficacy of pegcetacoplan vs. iptacopan in patients with C3 glomerulopathy: indirect treatment comparisons: SA-PO0826. J. Am. Soc. Nephrol. 36(Suppl. 10), 10.1681 (2025). [Accessed 3 March 2026]. https:\/\/sciencelibrary.sobi.com\/sites\/default\/files\/documents\/Dixon_ITC_ASN2025_poster.pdf","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"e_1_3_9_27_2","doi-asserted-by":"crossref","first-page":"106335","DOI":"10.1016\/j.ekir.2026.106335","article-title":"WCN26-AB-9364. Clinical efficacy of pegcetacoplan versus iptacopan in patients with C3 glomerulopathy: indirect treatment comparison","volume":"11","author":"Dixon BP","year":"2025","unstructured":"Dixon BP, Bomback AS, Rich CS WCN26-AB-9364. Clinical efficacy of pegcetacoplan versus iptacopan in patients with C3 glomerulopathy: indirect treatment comparison. Kidney Int. Rep. 11(Suppl. 4), 106335 (2025).","journal-title":"Kidney Int. Rep."},{"key":"e_1_3_9_28_2","article-title":"Pegcetacoplan versus iptacopan for the treatment of patients with C3 glomerulopathy: indirect treatment comparisons","author":"Dixon BP","year":"2026","unstructured":"Dixon BP, Bomback AS, Rich C Pegcetacoplan versus iptacopan for the treatment of patients with C3 glomerulopathy: indirect treatment comparisons. Adv. Ther. doi: 10.1007\/s12325-026-03614-3 (2026) (Epub ahead of print).","journal-title":"Adv. Ther."},{"issue":"1","key":"e_1_3_9_29_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/jmahp14010014","article-title":"Can we trust PAICs in rare diseases? Methodological challenges and limitations","volume":"14","author":"Parkitny M","year":"2026","unstructured":"Parkitny M, Aball\u00e9a S, Wojciechowski P, Toumi M. Can we trust PAICs in rare diseases? Methodological challenges and limitations. J. Mark. Access Health Policy 14(1), 14 (2026).","journal-title":"J. Mark. Access Health Policy"},{"issue":"6","key":"e_1_3_9_30_2","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research","volume":"15","author":"Signorovitch JE","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health 15(6), 940\u2013947 (2012).","journal-title":"Value Health"},{"key":"e_1_3_9_31_2","volume-title":"Heterogeneity: subgroups, meta-regression, bias and bias-adjustment [Internet]","author":"Dias S","year":"2012","unstructured":"Dias S, Sutton AJ, Welton NJ Heterogeneity: subgroups, meta-regression, bias and bias-adjustment [Internet]. National Institute for Health and Care Excellence (NICE), UK, NICE DSU Technical Support Document No. 3 (2012)."},{"issue":"1","key":"e_1_3_9_32_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ekir.2025.10.020","article-title":"Current and emerging therapies for C3 glomerulopathy and primary (idiopathic) immune complex membranoproliferative glomerulonephritis","volume":"11","author":"Kavanagh D","year":"2025","unstructured":"Kavanagh D, Ariceta G, Vivarelli M Current and emerging therapies for C3 glomerulopathy and primary (idiopathic) immune complex membranoproliferative glomerulonephritis. Kidney Int. Rep. 11(1), 17\u201331 (2025).","journal-title":"Kidney Int. Rep."},{"issue":"3","key":"e_1_3_9_33_2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1017\/S0266462319000333","article-title":"Population adjustment methods for indirect comparisons: a review of National Institute for Health and Care Excellence Technology Appraisals","volume":"35","author":"Phillippo DM","year":"2019","unstructured":"Phillippo DM, Dias S, Elsada A, Ades AE, Welton NJ. Population adjustment methods for indirect comparisons: a review of National Institute for Health and Care Excellence Technology Appraisals. Int. J. Technol. Assess. Health Care 35(3), 221\u2013228 (2019).","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"e_1_3_9_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.07.001"},{"issue":"30","key":"e_1_3_9_35_2","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1002\/sim.8759","article-title":"Assessing the performance of population adjustment methods for anchored indirect comparisons: a simulation study","volume":"39","author":"Phillippo DM","year":"2020","unstructured":"Phillippo DM, Dias S, Ades A, Welton NJ. Assessing the performance of population adjustment methods for anchored indirect comparisons: a simulation study. Stat. Med. 39(30), 4885\u20134911 (2020).","journal-title":"Stat. Med."},{"issue":"3","key":"e_1_3_9_36_2","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/rssa.12579","article-title":"Multilevel network meta-regression for population-adjusted treatment comparisons","volume":"183","author":"Phillippo DM","year":"2020","unstructured":"Phillippo DM, Dias S, Ades A Multilevel network meta-regression for population-adjusted treatment comparisons. J. R. Stat. Soc. Ser. A Stat. Soc. 183(3), 1189\u20131210 (2020).","journal-title":"J. R. Stat. Soc. Ser. A Stat. Soc."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2026-0054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:45:33Z","timestamp":1788263133000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2026-0054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.57264\/cer-2026-0054"],"URL":"https:\/\/doi.org\/10.57264\/cer-2026-0054","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"article-number":"e260054"}}